Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69:7–34.
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA. 2016;315:2564–2575.
   PubMed Web of Science ®Google Scholar
• Frazier AL, Colditz GA, Fuchs CS, et al. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 2000;284:1954–1961.
   PubMed Web of Science ®Google Scholar
• Goede SL, Kuntz KM, van Ballegooijen M, et al. Cost-savings to medicare from pre-medicare colorectal cancer screening. Med Care. 2015;53:630–638.
   PubMed Web of Science ®Google Scholar
• Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US preventive services task force. JAMA. 2016;315:2595–2609.
   PubMed Web of Science ®Google Scholar
• Subramanian S, Bobashev G, Morris RJ. Modeling the cost-effectiveness of colorectal cancer screening: policy guidance based on patient preferences and compliance. Cancer Epidemiol Biomark Prev. 2009;18:1971–1978.
   PubMed Web of Science ®Google Scholar
• Vijan S, Hwang EW, Hofer TP, et al. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med. 2001;111:593–601.
   PubMed Web of Science ®Google Scholar
• Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. A Cancer J Clin. 2018;68:250–281.
   PubMed Web of Science ®Google Scholar
• Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008;103:1541–1549.
   PubMed Web of Science ®Google Scholar
• Doubeni CA, Corley DA, Quinn VP, et al. Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study. Gut. 2018;67:291–298.
   PubMed Web of Science ®Google Scholar
• Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369:1095–1105.
   PubMed Web of Science ®Google Scholar
• Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366:2345–2357.
   PubMed Web of Science ®Google Scholar
• Segnan N, and the SCORE Working Group, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial–SCORE. J Natl Cancer Inst. 2011;103:1310–1322.
   PubMed Web of Science ®Google Scholar
• Atkin W, Wooldrage K, Parkin DM, et al. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet. 2017;389:1299–1311.
   PubMed Web of Science ®Google Scholar
• Ranasinghe I, Parzynski CS, Searfoss R, et al. Differences in colonoscopy quality among facilities: development of a post-colonoscopy risk-standardized rate of unplanned hospital visits. Gastroenterology. 2016;150:103–113.
   PubMed Web of Science ®Google Scholar
• Ko CW, Riffle S, Michaels L, et al. Serious complications within 30 days of screening and surveillance colonoscopy are uncommon. Clin Gastroenterol Hepatol. 2010;8:166–173.
   PubMed Web of Science ®Google Scholar
• Fisher DA, Maple JT, Ben-Menachem T, et al. Complications of colonoscopy. Gastrointest Endosc. 2011;74:745–752.
   PubMed Web of Science ®Google Scholar
• Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the medicare population. Ann Intern Med. 2009;150:849–857.
   PubMed Web of Science ®Google Scholar
• Imperiale TFR, Itzkowitz DF, H S. Multitarget stool DNA testing for colorectal-cancer screening. New Eng J Med. 2014;371:184–188.
   Google Scholar
• Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. multi-society task force on colorectal cancer. Am J Gastroenterol. 2017;112:1016–1030.
   PubMed Web of Science ®Google Scholar
• Cancer Intervention and Surveillance Modeling Network (CISNET). Joint Profile of Colorectal Cancer Model Profiles. 2018 [cited 2019 Mar 25]. Available from: https://cisnet.flexkb.net/mp/pub/cisnet_colorectal_joint_profile.pdf#pagemode=bookmarks
   Google Scholar
• Musgrove P, Fox-Rushby J. Cost-effectiveness analysis for priority setting. In: Jamison DT, Breman JG, Measham AR, et al., editors. Disease control priorities in developing countries. Washington (DC): World Bank The International Bank for Reconstruction and Development/The World Bank Group; 2006.
   Google Scholar
• Mezzio D, Brown D. Assessing drug price changes over 1 year and their influence on budget impact. Baltimore (MD): ISPOR International Society of Pharmacoeconomics and Outcomes Research; 2018.
   Google Scholar
• Appukkuttan S, Duchesneau E, Zichlin ML, et al. A budget impact analysis of the introduction of copanlisib for treatment of relapsed follicular lymphoma in the United States. JMCP. 2019;4:1–12.
   Google Scholar
• U.S. Census Bureau. Population Estimates by Age, Sex, Race and Hispanic Origin: United States Census Bureau. 2018 [cited 2018 Dec 1]. Available from: https://www.census.gov/newsroom/press-kits/2018/estimates-characteristics.html
   Google Scholar
• Burt RW. Colon cancer screening. Gastroenterology. 2000;119:837–853.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Colorectal Cancer Screening: What Are My Options? 2019 [updated 2019 Feb 26; cited 2019 Aug 13]. Available from: https://www.cancer.org/latest-news/understanding-tests-that-screen-for-colon-cancer.html
   Google Scholar
• Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US multi-society task force on colorectal cancer. Gastroenterology. 2012;143:844–857.
   PubMed Web of Science ®Google Scholar
• Govani SM, Elliott EE, Menees SB, et al. Predictors of suboptimal bowel preparation in asymptomatic patients undergoing average-risk screening colonoscopy. World J Gastrointest Endosc. 2016;8:616–622.
   PubMed Web of Science ®Google Scholar
• Day LW, Kwon A, Inadomi JM, et al. Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointest Endosc. 2011;74:885–896.
   PubMed Web of Science ®Google Scholar
• Ko CW, Riffle S, Shapiro JA, et al. Incidence of minor complications and time lost from normal activities after screening or surveillance colonoscopy. Gastrointest Endosc. 2007;65:648–656.
   PubMed Web of Science ®Google Scholar
• Leffler DA, Kheraj R, Garud S, et al. The incidence and cost of unexpected hospital use after scheduled outpatient endoscopy. Arch Intern Med. 2010;170:1752–1757.
   PubMedGoogle Scholar
• Chukmaitov AS, Menachemi N, Brown SL, et al. Is there a relationship between physician and facility volumes of ambulatory procedures and patient outcomes? J Ambulatory Care Manage. 2008;31:354–369.
   PubMedGoogle Scholar
• Manufacturer data on file. 2019. Mt-sDNA’s compliance rate represents the cumulative completed tests from kits shipped to patients during the six-month period ending 12 months prior to the end of the 2019, excluding program orders.
   Google Scholar
• van Roon AH, Goede SL, van Ballegooijen M, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut. 2013;62:409–415.
   PubMed Web of Science ®Google Scholar
• Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort studyfecal immunochemical test performance characteristics. Ann Intern Med. 2016;164:456–463.
   PubMed Web of Science ®Google Scholar
• Chyhaniuk A, Coombes ME. Longitudinal adherence to colorectal cancer screening guidelines. Am J Manag Care. 2016;22:105–111.
   PubMed Web of Science ®Google Scholar
• Administration USFD. FDA Summary of Safety and Effectiveness Data. 2018.
   Google Scholar
• Centers for Medicare & Medicaid Services. Clinical Laboratory Fee Schedule. Baltimore (MD); 2019 Jun 1. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files.html
   Google Scholar
• Healthcare Bluebook. Binding price estimate for Anesthesia for colonoscopy (with biopsy). Available from: https://www.healthcarebluebook.com/
   Google Scholar
• Pyenson B, Scammell C, Broulette J. Costs and repeat rates associated with colonoscopy observed in medical claims for commercial and Medicare populations. BMC Health Serv Res. 2014;14:92.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. Physician Fee Schedule cms.gov. 2019 May 1. Available from: https://www.cms.gov/apps/physician-fee-schedule/overview.aspx
   Google Scholar
• Healthcare Cost and Utilizaiton Project (HCUP). HCUP NIS Database Documentation. Rockville (MD); 2018 Dec 1. Available from: https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp
   Google Scholar
• Hathway J, Jensen I, Cyr P, et al. Economic analysis of colorectal cancer screening from multiple stakeholder perspectives: key components to improve practical applications in the US. New Orleans (LA): ISPOR International Society for Pharmacoeconomics and Outcomes Research; 2019.
   Google Scholar
• F1ederal Reserve Bank of St. Louis. Federal Reserve Economic Data. St. Louis (MO); 2019 [cited 2019 Jun 1]. Available from: https://fred.stlouisfed.org/series/CPIAUCSL#0
   Google Scholar
• Subramanian S, Tangka FKL, Hoover S, et al. Costs of colorectal cancer screening provision in CDC’s colorectal cancer control program: comparisons of colonoscopy and FOBT/FIT based screening. Eval Prog Plan. 2017;62:73–80.
   PubMed Web of Science ®Google Scholar
• Leard LE, Savides TJ, Ganiats TG. Patient preferences for colorectal cancer screening. J Fam Pract. 1997;45:211–218.
   PubMed Web of Science ®Google Scholar
• Phillips AK, Liang LY, Ladabaum LU, et al. Trends in colonoscopy for colorectal cancer screening. Med Care. 2007;45:160–167.
   PubMed Web of Science ®Google Scholar
• Rutter CM, Yu O, Miglioretti DL. A hierarchical non-homogenous Poisson model for meta-analysis of adenoma counts. Statist Med. 2007;26:98–109.
   PubMed Web of Science ®Google Scholar
• Zauber A, Knudsen A, Rutter C, et al. Evaluating the benefits and harms of colorectal cancer screening strategies: a collaborative modeling approach. 2015.
   Google Scholar
• Zauber AG, Lansdorp-Vogelaar I, Wilschut J, et al. AHRQ technology assessments. Cost-effectiveness of DNA stool testing to screen for colorectal cancer. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007.
   Google Scholar
• Healthcare Cost and Utilization Project (HCUP). HCUP CCS—Services and Procedures. Rockville (MD); 2018. Available from: https://www.hcup-us.ahrq.gov/toolssoftware/ccs_svcsproc/ccssvcproc.jsp
   Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316:1093–1103.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford Univ. Press; 2011.
   Google Scholar
• Subramanian S, Tangka FKL, Hoover S, et al. Costs of planning and implementing the CDC’s colorectal cancer screening demonstration program. Cancer. 2013;119:2855–2862.
   PubMed Web of Science ®Google Scholar
• Subramanian S, Tangka FKL, Hoover S, et al. Comparison of program resources required for colonoscopy and fecal screening: findings from 5 years of the colorectal cancer control program. Prev Chronic Dis. 2019;16:E50.
   PubMed Web of Science ®Google Scholar
• Silva-Illanes N, Espinoza M. Critical analysis of Markov models used for the economic evaluation of colorectal cancer screening: a systematic review. Value Health. 2018;21:858–873.
   PubMed Web of Science ®Google Scholar
• Doubeni CA, Fedewa SA, Levin TR, et al. Modifiable failures in the colorectal cancer screening process and their association with risk of death. Gastroenterology. 2019;156:63–74.e6.
   PubMedGoogle Scholar
• Soerjomataram I, Thong MS, Ezzati M, et al. Most colorectal cancer survivors live a large proportion of their remaining life in good health. Cancer Causes Control. 2012;23:1421–1428.
   PubMed Web of Science ®Google Scholar
• Anderson LM, May DS. Has the use of cervical, breast, and colorectal cancer screening increased in the United States? Am J Public Health. 1995;85:840–842.
   PubMed Web of Science ®Google Scholar
• Brown ML, Potosky AL, Thompson GB, et al. The knowledge and use of screening tests for colorectal and prostate cancer: data from the 1987 National Health Interview Survey. Prevent Med. 1990;19:562–574.
   PubMed Web of Science ®Google Scholar